55
https://pubmed.ncbi.nlm.nih.gov/38116724
The study found that doravirine exposure is elevated in people with obesity, but remains within the safe range, not requiring dose modification.
“Doravirine Exposure Unaltered in Obese Individuals, No Dose Modification Necessary”
